As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door

Despite the recent emergence of a new drug class, schizophrenia remains one of the most challenging neuropsychiatric diseases to treat—and Cobenfy’s first steps into the market indicate there is still room to grow.